Supplemental Fig. 1 Fluorescence spectra of HPPH-CD in ex vivo organs of ICR mice bearing S180 subcutaneous tumors when excited at 785 nM.

Supplemental Fig. 2 Whole body images (A) and fluorescence intensity (B) of tumors in S180 tumor-bearing mice administrated with HPPH-CD at 0.5 mg/kg at various time points, the mice were anesthetized each time point for fluorescence imaging. Ex vivo fluorescence imaging (C) of tumor and major organs collected after whole body imaging at 240 h post HPPH-CD delivery. Green words were fluorescence intensity of tumor, liver, kidney, skin, spleen, and they were detected to be 94.121, 61.127, 37.408, 55.097, and 154.24, respectively, which were shown in (d).

Supplemental Fig. 3 (A)Body weight of normal mice administrated with vehicle and model mice administrated with B(a)P. The body weight were recorded weekly for 20 weeks. (B) Images of stomachs under standard brightfield: (a) a stomach from normal group, (b-g) stomach from model mice administrated with B(a)P. The circles and arrows indicated location of the tumors.

Supplemental Fig. 4 (A)Body weight of normal rats administrated with vehicle and model rats administrated with MNNG. The body weight were recorded weekly for 46 weeks. (B) Images of stomachs and duodenums under standard brightfield: (a) a stomach from normal group, (b-e) stomachs from model rat administrated with MNNG. (f-g) duodenums from model rat administrated with MNNG. The arrows indicated location of the tumors.

Supplemental Fig. 1 Fluorescence spectra of HPPH-CD in ex vivo organs of ICR mice bearing S180 subcutaneous tumors when excited at 785 nM.



Supplemental Fig. 2 Whole body images (A) and fluorescence intensity (B) of tumors in S180 tumor-bearing mice administrated with HPPH-CD at 0.5 mg/kg at various time points, the mice were anesthetized each time point for fluorescence imaging. Ex vivo fluorescence imaging (C) of tumor and major organs collected after whole body imaging at 240 h post HPPH-CD delivery. Green words were fluorescence intensity of tumor, liver, kidney, skin, spleen, and they were detected to be 94.121, 61.127, 37.408, 55.097, and 154.24, respectively, which were shown in (d).



Supplemental Fig. 3 (A)Body weight of normal mice administrated with vehicle and model mice administrated with B(a)P. The body weight were recorded weekly for 20 weeks. (B) Images of stomachs under standard brightfield: (a) a stomach from normal group, (b-g) stomach from model mice administrated with B(a)P. The circles and arrows indicated location of the tumors.



Supplemental Fig. 4 (A)Body weight of normal rats administrated with vehicle and model rats administrated with MNNG. The body weight were recorded weekly for 46 weeks. (B) Images of stomachs and duodenums under standard brightfield: (a) a stomach from normal group, (b-e) stomachs from model rat administrated with MNNG. (f-g) duodenums from model rat administrated with MNNG. The arrows indicated location of the tumors.